Roche Diversifies With $105m-Plus Adheron Buy
This article was originally published in Scrip
Executive Summary
Roche will pay $105m up front and up to $475m in milestone fees to acquire Adheron Therapeutics in a deal that may help expand the Swiss big pharma portfolio in the company's key therapeutic areas outside of oncology.